Search

Search Results

• Stronger Together: How GLP-1 RAs and SGLT-2 Inhibitors Revolutionize Type 2 Diabetes Treatment

  Hanna Sitarek, Adrianna Tabeau, Joanna Prus, Justyna Pięta, Agnieszka Pawlik, Patryk Dudek, Klaudia Łuczak, Wiktoria Ulicka, Marcel Chudzikowski, Agata Prokopiuk

  59642

  2025-05-06
• SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review

  Michał Szczepański, Marcin Kuliga, Mateusz Bajak, Julia Słowik, Julia Inglot, Jadwiga Inglot, Dominik Maciej Feret, Daniel Zapasek, Maciej Mamczur, Damian Sowa

  56369

  2024-12-08
• Innovations in Pharmacotherapy of Diabetes: A Review of Latest Reports

  Katarzyna Czechowska, Aleksandra Świerczewska, Piotr Komasara, Julia Nowakowska, Aleksandra Sędek, Lena Merchel, Ilona Bednarek, Sylwia Lach, Karol Seweryn Błąd, Kinga Kałuża

  61795

  2025-07-08
• Morphological changes in kidney glomeruli of rats with chronic toxic hepatitis and its correction with lisinopril, L-arginine-L-glutamate and their combination

  N. A. Rykalo, Yu. M. Berehovenko, O. V. Androshchuk

  632-639

  2019-05-27
• Effect of ras-blockers and no-cycle metabolites on the renal functions of rats exposed to thyroxine injections

  S. I. Dolomatov, T. P. Sataieva

  41-55

  2014-01-12
• GLP-1 and SGLT2 Therapies in Type 2 Diabetes Mellitus. Cutting-Edge Approaches to Advancing Diabetes Care

  Agnieszka Parfianowicz, Alicja Surma

  57478

  2025-02-04
• GLP-1 Receptor Agonists: A New Hope in the Global Fight Against Obesity — Benefits and Health Risks

  Oskar Pastuszek, Konrad Borowski, Maja Radziwon, Emilia Bolesta-Okuniewska, Paweł Michalak, Aleksandra Marchwińska-Pancer, Katarzyna Kopeć, Julia Ceryn, Anna Wicher

  67433

  2026-01-11